Coty Wade
Family · Tuscaloosa, ALNPI 1144305053
Payments from drug & device makers
Across 459 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$815
- Amgen$569
- AbbVie$533
- GSK$508
- Optinose US, Inc.$452
- AstraZeneca$393
- plus $3K from 41 others
What the payments were for
- Food & beverage$6,740100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,749 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $82,519 |
| JardianceEmpagliflozin | 42 | $42,481 |
| MounjaroTirzepatide | 33 | $33,650 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 42 | $29,677 |
| EliquisApixaban | 34 | $22,045 |
| JanuviaSitagliptin Phosphate | 30 | $20,667 |
| FarxigaDapagliflozin Propanediol | 14 | $17,000 |
| RybelsusSemaglutide | 12 | $14,352 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $13,085 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $9,569 |
| MyrbetriqMirabegron | 13 | $6,641 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,831 |
| Rosuvastatin Calcium | 237 | $3,500 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $2,723 |
| Omeprazole | 191 | $2,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $815 | $96,87190 claims |
| MerckJanumet Xr, Januvia, Janumet | $104 | $59,91383 claims |
| Boehringer IngelheimJardiance, Glyxambi | $192 | $55,56659 claims |
| Lilly USA, LLCMounjaro | $308 | $33,65033 claims |
| PfizerEliquis | $215 | $22,04534 claims |
| AstraZenecaFarxiga | $393 | $17,00014 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $6,64113 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $2,72313 claims |
| AbbVieSynthroid | $533 | $1,43817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Tuscaloosa
- Justin SimpsonTuscaloosa$43K
- Ashley StinesTuscaloosa$29K
- Lauren KyzarTuscaloosa$17K
- Dee GuyTuscaloosa$14K
- Haley TippsTuscaloosa$14K
- Jeremy KelleyTuscaloosa$13K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.